Search company, investor...

Chimeric Therapies

tart.cortera.com

Stage

Unattributed VC | Alive

Total Raised

$33.52M

Last Raised

$9.7M | 21 yrs ago

About Chimeric Therapies

Developer of bone marrow graft engineering to expand the use of safe and effective cellular grafts tailored to treat and cure diseases of the immune system and blood system.

Headquarters Location

28202 Cabot Road Suite 210

Laguna Niguel, California, 92677,

United States

949-347-9640

Missing: Chimeric Therapies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Chimeric Therapies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Chimeric Therapies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Chimeric Therapies is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Chimeric Therapies Frequently Asked Questions (FAQ)

  • Where is Chimeric Therapies's headquarters?

    Chimeric Therapies's headquarters is located at 28202 Cabot Road Suite 210, Laguna Niguel.

  • What is Chimeric Therapies's latest funding round?

    Chimeric Therapies's latest funding round is Unattributed VC.

  • How much did Chimeric Therapies raise?

    Chimeric Therapies raised a total of $33.52M.

  • Who are the investors of Chimeric Therapies?

    Investors of Chimeric Therapies include Bioscience Investment Trust PLC, Leeway & Co, Sofinnova Ventures, Alloy Ventures, Domain Associates and 4 more.

  • Who are Chimeric Therapies's competitors?

    Competitors of Chimeric Therapies include United Biomedical, Immune Design, Intarcia Therapeutics, Theraclone Sciences, Tolera Therapeutics and 11 more.

Compare Chimeric Therapies to Competitors

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

L
Leuko Bioscience

Leuko Bioscience is aimed at treating diseases of the immune system

I
ISA Pharmaceuticals

ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

M
Mimetix Pharmaceuticals

Free Radical Scavengers developed from Duke's BME Department for treating and preventing diseases from occurring.

O
Osteologix

Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.